Survivorship research established investigator award

生存研究设立研究者奖

• 批准号: 8282597
• 负责人: CHARLES L LOPRINZI
• 金额: $ 15.61万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8282597
• 关键词: Area; Award; Back; Cancer Control; Cancer Etiology; Chemoprevention; Clinic; Clinical Investigator; Clinical Research; Community Clinical Oncology Program; Complementary and alternative medicine; Comprehensive Cancer Center; Conduct Clinical Trials; Development; Fruit; Funding; Grant; Individual; Inservice Training; Investigation; Leadership; Malignant Neoplasms; Manuscripts; Mentors; Mentorship; North Central Cancer Treatment Group; Patient Care; Persons; Principal Investigator; Process; Protocols documentation; Publishing; Reporting; Research; Research Personnel; Research Scientist Award; Role; Running; Symptoms; Time; base; cancer prevention; cancer therapy; career; design; experience; improved; interest; next generation; oncology; programs; response; survivorship

DESCRIPTION (provided by applicant): The specific aim of this grant is to mentor young clinical investigators, primarily in the area of research related to the control of symptoms caused by cancer and/or cancer therapy. A time comes in an investigator's career when a previously mentored person becomes the mentor. Although it might not be easy to admit, being more than half way through my career, I have made the transformation from primarily being mentored, to being a mentor. I am currently the Director of the Cancer Control Program of the North Central Cancer Treatment Group (NCCTG) as well as the co-director of the Cancer Prevention and Control Program of the Mayo Clinic Comprehensive Cancer Center. I have been the Principal Investigator of a community clinical oncology program (CCOP) research base grant for over a decade and have received R01 grant funding in the past. The last two competitive renewals of the CCOP research base grant that I submitted both received an identical outstanding score, that being 123. Through this effort, I have, arguably, developed the most productive program in the world designed to evaluate means of alleviating symptoms caused by cancer and/or cancer therapy. Using this background, with the funds obtained from this grant I will provide mentorship for young clinical investigators interested in a career in clinical research related to relief of symptoms from cancer and/or cancer therapy. I will use an "on-the-job" training approach to help them with the development of applicable protocols. I will mentor them through the protocol review process, through the conduct of the clinical trial, and through the process to report results as a manuscript. I will facilitate their leadership of subsections of the Mayo Oncology Symptom Control Program. I will facilitate their development of independent grant funding. I view this as a process of succession planning, expecting that one or more of these mentored individuals will eventually take my place and continue to promulgate the symptom control research program that we have here, allowing them to mentor the next generation of investigators. This role as a mentor allows me to give back to the scientific field some of the fruits from the mentoring that was provided to me in my early career. This should allow for continued investigation for promising means for alleviating symptoms related to cancer and/or cancer therapy. This will allow for improved care of patients with cancer.

该补助金的具体目的是指导年轻的临床研究人员，主要是在与控制癌症和/或癌症治疗引起的症状相关的研究领域。 在调查员的职业生涯中，有一段时间以前接受过指导的人成为了导师。虽然这可能不容易承认，在我职业生涯的一半以上，我已经从主要的指导转变，成为一个导师。 我目前是北中央癌症治疗小组（NCCTG）癌症控制项目的主任，也是马约诊所综合癌症中心癌症预防和控制项目的联合主任。十多年来，我一直是社区临床肿瘤学项目（CCOP）研究基地补助金的主要研究者，过去曾获得R 01补助金。我提交的CCOP研究基础补助金的最后两次竞争性更新都获得了相同的优秀分数，即123分。通过这一努力，我可以说开发了世界上最富有成效的项目，旨在评估缓解癌症和/或癌症治疗引起的症状的方法。 利用这一背景，从这笔赠款中获得的资金，我将为有兴趣从事与缓解癌症症状和/或癌症治疗相关的临床研究的年轻临床研究人员提供指导。我将使用“在职”培训方法来帮助他们制定适用的协议。我将指导他们通过方案审查过程，通过临床试验的进行，并通过过程报告结果作为手稿。我将协助他们领导马约肿瘤症状控制项目的各个部分。我将促进他们发展独立的赠款资金。我认为这是一个继任计划的过程，希望这些指导的个人中的一个或多个最终会取代我的位置，继续颁布我们在这里的症状控制研究计划，让他们指导下一代的研究人员。 作为导师的角色让我能够回馈科学领域的一些成果，这些成果来自于我早期职业生涯中提供给我的指导。这将允许继续研究有希望的缓解癌症和/或癌症治疗相关症状的方法。这将有助于改善对癌症患者的护理。

项目成果

An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.

• DOI: 10.1007/s00520-014-2326-9
• 发表时间: 2015-01
• 期刊: SUPPORTIVE CARE IN CANCER
• 影响因子: 3.1
• 作者: Hegerova, Livia T.;Leal, Alexis D.;Grendahl, Darryl C.;Seisler, Drew K.;Sorgatz, Kristine M.;Anderson, Kari J.;Hilger, Crystal R.;Loprinzi, Charles L.
• 通讯作者: Loprinzi, Charles L.

Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis.

• DOI: 10.1097/gme.0b013e31818c91ca
• 发表时间: 2009-05
• 期刊: Menopause (New York, N.Y.)
• 作者: Bardia A;Novotny P;Sloan J;Barton D;Loprinzi C
• 通讯作者: Loprinzi C

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.

• DOI: 10.1200/jco.2010.30.3644
• 发表时间: 2011
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: D. Steensma;J. Sloan;S. Dakhil;R. Dalton;S. Kahanic;D. Prager;P. Stella;K. Rowland;P. Novotny;C. Loprinzi

Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.

更年期相关血管舒缩症状的管理：当前的治疗选择、挑战和未来方向。

• DOI: 10.2147/ijwh.s7721
• 发表时间: 2010
• 期刊: International journal of women's health
• 作者: Pachman,DeirdreR;Jones,JasonM;Loprinzi,CharlesL
• 通讯作者: Loprinzi,CharlesL

Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.

• DOI: 10.1007/s00520-014-2424-8
• 发表时间: 2015-04
• 期刊: SUPPORTIVE CARE IN CANCER
• 影响因子: 3.1
• 作者: Pachman, Deirdre R.;Weisbrod, Breanna L.;Seisler, Drew K.;Barton, Debra L.;Fee-Schroeder, Kelliann C.;Smith, Thomas J.;Lachance, Daniel H.;Liu, Heshan;Shelerud, Randy A.;Cheville, Andrea L.;Loprinzi, Charles L.
• 通讯作者: Loprinzi, Charles L.